U.S. Portable Point-of-Care Testing Devices Market

Market Outlook

By 2035, the U.S. Portable Point-of-Care Testing Devices Market is expected to reach approximately USD 21.98 billion, expanding at a CAGR of 9.65% during the forecast period 2026–2035. The market is estimated at USD 8.75 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

For this report, portable point-of-care testing devices comprise handheld, compact, transportable, and decentralized diagnostic systems designed to generate clinically actionable results at or near the patient. The scope includes portable blood chemistry and blood gas analyzers, glucose and metabolic testing systems, compact immunoassay readers, portable molecular diagnostic platforms, coagulation systems, hematology devices, urinalysis analyzers, and the dedicated cartridges, test cards, reagents, and consumables required for their operation. Large central-laboratory analyzers, diagnostic imaging systems, and general physiologic monitoring equipment are excluded.

The U.S. market is entering a new phase in which portability is no longer viewed merely as a convenience feature. Hospitals, physician offices, urgent care networks, emergency medical services, retail clinics, specialty practices, rural facilities, and community health programs increasingly evaluate portable diagnostics as a means of compressing the time between specimen collection, diagnosis, and treatment. This workflow advantage is especially important in emergency medicine, infectious disease, diabetes care, anticoagulation management, renal disease, cardiometabolic assessment, and settings where access to a full laboratory is limited.

The historical market is estimated to have increased from approximately USD 5.92 billion in 2021 to USD 7.96 billion in 2024, supported by sustained decentralization of diagnostic testing, normalization of outpatient volumes after the pandemic, growth in urgent care utilization, increasing adoption of connected glucose and chemistry platforms, and continuing investment in rapid infectious disease testing. The market reached approximately USD 8.75 billion in 2025 as healthcare providers moved from temporary pandemic-era testing infrastructure toward more permanent decentralized diagnostic strategies.

Growth is expected to accelerate as compact molecular diagnostics, multiplex testing, microfluidics, AI-assisted hematology, wireless connectivity, automatic quality control, cloud-based device management, and electronic medical record integration improve the economics and clinical reliability of near-patient testing. Under the forecast model, the market is expected to reach approximately USD 9.59 billion in 2026, USD 13.87 billion by 2030, and USD 21.98 billion by 2035.

One of the most important commercial characteristics of the market is its recurring-revenue structure. Manufacturers may place analyzers at relatively low upfront cost while generating long-term revenue from proprietary cartridges, cassettes, strips, test cards, controls, and reagents. Consequently, hospital buyers increasingly evaluate the total cost per reportable result, reagent utilization, test-menu breadth, instrument uptime, connectivity, quality-control burden, operator training requirements, and potential reduction in laboratory turnaround time rather than evaluating instrument acquisition price alone.

Portable testing is also becoming increasingly relevant to U.S. healthcare labor economics. Diagnostic systems that can be operated safely by non-laboratory personnel under appropriate regulatory conditions have strategic value at a time when health systems are attempting to reduce workflow friction, improve emergency department throughput, shorten time to treatment, and extend diagnostic capabilities across distributed outpatient networks.

Introduction

According to the U.S. Portable Point-of-Care Testing Devices Market Report, the market sits at the intersection of clinical diagnostics, decentralized healthcare delivery, digital connectivity, and workflow automation. Unlike conventional laboratory testing, which requires specimens to move through centralized collection, transportation, accessioning, processing, analysis, and reporting workflows, portable point-of-care testing moves the diagnostic capability closer to the clinical decision.

The U.S. provides an unusually attractive environment for portable diagnostic technologies because of its large healthcare infrastructure, high chronic disease burden, extensive physician office and urgent care network, mature medical device industry, established reimbursement system, and concentration of FDA-regulated diagnostic innovation. More than 6,000 hospitals, over 900,000 staffed hospital beds, and approximately 35 million annual hospital admissions provide a large institutional base for bedside and near-patient testing. At the same time, more than 15,000 urgent care centers have created a sizable decentralized channel in which rapid results can directly influence prescribing, referral, patient disposition, and treatment decisions during a single encounter.

Disease burden further strengthens demand. Approximately 40.1 million people in the United States were estimated to have diagnosed or undiagnosed diabetes in 2023, creating a large clinical requirement for glucose, HbA1c, renal, electrolyte, and metabolic monitoring. More than 35 million U.S. adults are estimated to have chronic kidney disease, while infectious disease remains a significant point-of-care testing opportunity. More than 2.2 million combined cases of chlamydia, gonorrhea, and syphilis were reported in the United States in 2024, illustrating the potential value of same-visit molecular and immunoassay testing.

The clinical value proposition varies significantly by setting. In the emergency department, a result delivered within minutes may support triage, sepsis evaluation, electrolyte correction, blood gas interpretation, lactate measurement, or anticoagulation decisions. In urgent care, respiratory and molecular tests can support same-visit antiviral or antimicrobial decisions. In diabetes clinics, portable HbA1c systems can eliminate the need to wait for off-site laboratory results before modifying therapy. In rural care, portability can reduce the logistical disadvantage associated with distance from centralized laboratories.

The market is therefore moving away from isolated single-analyte meters toward connected diagnostic ecosystems. Buyers increasingly prefer systems that combine a broad test menu with barcode identification, automatic calibration, operator lockout, quality-control management, wireless result transmission, cloud connectivity, cybersecurity controls, and integration with laboratory information systems or electronic health records.

The economic argument is equally important. Portable testing does not automatically reduce laboratory cost because cartridges can carry a higher unit price than centralized tests. The strongest value proposition arises when rapid diagnostics alter patient flow or clinical decision-making. A portable test can generate attractive economics when it avoids an unnecessary admission, reduces emergency department waiting time, prevents repeat appointments, accelerates treatment, improves operating room workflow, or reduces specimen transportation and laboratory staffing requirements.

For manufacturers, this means future market leadership will depend on more than analytical accuracy. Successful platforms will need to demonstrate usability, low error rates, reliable supply, clinically relevant turnaround time, connectivity, competitive cost per test, scalable quality assurance, and evidence that rapid results change care pathways.

Key Market Drivers: What’s Fueling the U.S. Portable Point-of-Care Testing Devices Market Boom?

The most important driver is the decentralization of diagnostic testing across the U.S. healthcare system. Care delivery is increasingly distributed across hospital departments, physician practices, urgent care clinics, retail health sites, ambulatory specialty centers, home-based programs, mobile health units, and rural facilities. Every additional site of care creates demand for testing solutions that do not depend on full central-laboratory infrastructure.

A second major driver is the continuing burden of chronic metabolic disease. Diabetes is particularly important because patients frequently require longitudinal glucose assessment, HbA1c testing, renal monitoring, and cardiometabolic risk evaluation. With tens of millions of Americans affected by diabetes and an even larger population at metabolic risk, portable glucose and chemistry testing retains a large recurring consumables base. The category is evolving from simple glucose meters toward connected multi-analyte platforms capable of supporting broader chronic disease management.

A third driver is rapid infectious disease diagnosis. Respiratory infections, sexually transmitted infections, hepatitis, strep throat, gastrointestinal infections, and other conditions benefit from faster identification when the test result can directly influence treatment. Molecular point-of-care systems are especially disruptive because they move PCR-quality or nucleic-acid amplification testing from centralized laboratories into urgent care centers, emergency departments, physician offices, and community clinics.

Recent U.S. regulatory activity demonstrates this direction. Point-of-care molecular systems now support rapid testing for respiratory pathogens, sexually transmitted infections, hepatitis C, and other conditions, with several systems receiving CLIA-waived status. The clinical implication is significant: diagnostic information that previously required hours or days can increasingly be generated during the patient encounter.

The fourth driver is the growth of urgent care and convenient care delivery. The U.S. urgent care sector now treats well over 100 million patient encounters annually across more than 15,000 centers. These facilities depend heavily on rapid diagnostic decision-making because their business model requires high patient throughput, limited on-site laboratory complexity, and the ability to treat or discharge patients efficiently. Compact immunoassay and molecular systems are therefore becoming core infrastructure rather than optional accessories.

A fifth driver is hospital workflow economics. U.S. hospitals are under sustained pressure to improve bed utilization, emergency department throughput, operating room efficiency, and clinical labor productivity. Portable blood gas, chemistry, coagulation, and lactate testing can remove transportation and laboratory processing time from critical workflows. The financial value can exceed the incremental test cost when minutes matter for patient disposition or procedural efficiency.

The sixth driver is the expanding availability of CLIA-waived testing. FDA categorization of tests as waived allows qualified testing sites operating under appropriate certificates to use simplified diagnostic systems outside traditional high-complexity laboratories. This materially expands the potential customer base for portable devices. Manufacturers increasingly design platforms around simplified sample handling, automated quality control, guided workflows, minimal maintenance, and integrated error detection because operational simplicity can be as commercially important as analytical performance.

The seventh driver is rural and underserved-care demand. Many U.S. communities face long travel distances to hospitals, specialist shortages, limited laboratory infrastructure, and logistical delays in specimen transportation. Portable testing can improve access when deployed through critical access hospitals, rural clinics, mobile units, community health centers, pharmacies, and outreach programs. This does not eliminate broader access challenges, but it can reduce one of the important operational barriers to timely diagnosis.

An eighth driver is the growing strategic importance of connectivity and informatics. Point-of-care programs become increasingly difficult to manage as hundreds or thousands of devices are distributed across a health system. Hospitals are therefore prioritizing analyzers capable of transmitting results automatically, managing operator credentials, documenting QC compliance, monitoring cartridge lots, and interfacing with LIS and EHR infrastructure. Connected devices reduce manual transcription risk and give laboratory leadership greater governance over decentralized testing.

Finally, U.S. purchasing behavior is shifting toward platform consolidation. Rather than supporting multiple unrelated analyzers with different cartridges, service agreements, interfaces, and training requirements, integrated health systems increasingly favor suppliers that can standardize testing across emergency departments, intensive care units, clinics, physician offices, and outpatient networks. Companies with broad assay menus and scalable informatics capabilities therefore have a structural advantage.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in portable point-of-care testing is increasingly centered on the question of how much laboratory capability can be compressed into a small, automated, clinically robust instrument. Miniaturization alone is no longer sufficient. The competitive frontier is defined by speed, multiplexing, analytical quality, ease of use, connectivity, test-menu breadth, and the ability to operate reliably across decentralized environments.

Ultra-fast molecular diagnostics represent one of the most important technology shifts. Conventional molecular testing historically required centralized instruments, trained laboratory personnel, batch processing, and significant infrastructure. New compact systems are reducing molecular turnaround times to approximately 10–30 minutes for selected assays, creating an entirely different clinical workflow. Respiratory testing is an early commercial focus because influenza, COVID-19, RSV, and other pathogens produce overlapping symptoms but may require different management.

The U.S. market is also seeing a transition from single-pathogen testing toward multiplex molecular panels. The ability to identify several clinically relevant pathogens from one specimen increases the information value of each patient encounter. However, manufacturers must balance panel breadth with cost because providers may resist paying for unnecessary targets. The most commercially successful systems are likely to align assay configuration closely with real-world treatment decisions.

Microfluidics and cartridge integration are another major innovation area. Portable analyzers increasingly place specimen preparation, reagent storage, calibration, reaction chambers, sensors, and waste containment into a disposable cartridge or test card. This moves complexity from the user into the consumable, improving usability and reducing contamination risk. The tradeoff is that cartridge economics become central to adoption because recurring consumable cost can materially affect total program expense.

Portable blood chemistry is also advancing through multi-analyte test cards. Handheld blood analyzers can generate blood gases, electrolytes, metabolites, glucose, creatinine, lactate, hematocrit, and related calculated parameters from small whole-blood samples. In emergency medicine and critical care, these systems have strategic value because they can place clinically important information at the bedside within minutes.

AI-enabled hematology and digital microscopy approaches are beginning to broaden the scope of portable testing. Newer systems use computer vision, advanced optics, and machine-learning algorithms to analyze blood-cell characteristics from small samples. If clinical performance, regulatory validation, and cost economics continue to improve, portable hematology could move selected CBC-related workflows closer to oncology clinics, pharmacies, physician offices, home health programs, and community settings.

Connectivity is becoming a core product requirement. Bluetooth, Wi-Fi, cloud connectivity, remote device management, automatic synchronization, and direct EHR/LIS transmission increasingly separate enterprise-ready platforms from stand-alone devices. Health systems are particularly sensitive to patient identification errors, manual transcription, unauthorized operators, overdue quality control, and disconnected records. Manufacturers that solve these governance problems can command stronger enterprise value.

Innovation is also shifting toward sample simplification. Fingerstick and low-volume capillary collection can reduce dependence on phlebotomy, particularly in outpatient, pediatric, home, and community environments. The commercial significance is substantial because a device that technically produces results quickly but requires a complicated venous collection workflow may offer limited practical advantage outside hospitals.

The regulatory strategy itself has become part of product design. Companies targeting decentralized U.S. settings increasingly engineer systems to support CLIA waiver, emphasizing simplicity, automated safeguards, limited hands-on steps, clear instructions, and reduced risk of operator error. This can materially expand the addressable market beyond conventional laboratories.

The next competitive phase will revolve around portable platforms rather than isolated tests. Manufacturers will seek to add assays over time to the same installed instrument, increasing instrument utilization and customer retention. A system initially purchased for respiratory testing may later support STI, gastrointestinal, coagulation, cardiac, inflammatory, renal, or metabolic assays. This installed-base strategy can produce attractive recurring economics and increase switching costs.

Segmentation Insights

The U.S. Portable Point-of-Care Testing Devices Market is segmented on the basis of product type, technology, application, end user, and region.

By Product Type

Handheld Blood Chemistry and Blood Gas Analyzers

Handheld chemistry and blood gas systems form one of the highest-value professional segments of the market. These devices measure combinations of blood gases, electrolytes, lactate, glucose, creatinine, hematocrit, and related parameters using disposable cartridges or test cards. Emergency departments, intensive care units, operating rooms, neonatal care, transport medicine, and critical access hospitals represent major customers. Their competitive advantage is based on minutes saved between sample collection and intervention.

The segment benefits from a strong recurring-consumables model and high clinical dependence. Hospitals typically prioritize analytical agreement with laboratory systems, cartridge stability, small sample volumes, device uptime, wireless connectivity, quality-control automation, and standardized deployment across multiple departments.

Portable Glucose, HbA1c and Metabolic Testing Systems

Glucose and metabolic testing represented the largest broad portable-testing category in 2025, supported by the scale of diabetes and cardiometabolic disease in the United States. This category includes professional glucose meters, portable HbA1c analyzers, lipid systems, ketone testing devices, creatinine systems, and multi-analyte metabolic platforms.

The category is gradually moving beyond individual glucose measurements toward broader metabolic decision support. Physician practices, diabetes clinics, pharmacies, endocrinology offices, primary care groups, and chronic disease programs increasingly value same-visit HbA1c or renal measurements because results can influence medication adjustment during the consultation.

Portable Immunoassay and Rapid-Test Readers

Compact immunoassay readers are widely used for respiratory infections, streptococcal disease, pregnancy, fertility, inflammatory markers, cardiac markers, and other rapid assays. Instrument-assisted reading reduces subjectivity compared with unaided visual interpretation and allows results to be electronically stored or transmitted.

Respiratory testing remains a major revenue contributor because of high seasonal testing volumes. The longer-term growth opportunity will come from expanding analyte menus and integrating objective digital interpretation with connectivity platforms.

Portable Molecular Diagnostic Systems

Portable molecular diagnostics are expected to be the fastest-growing product type through 2035. Compact PCR and nucleic-acid amplification platforms increasingly deliver laboratory-grade molecular information in decentralized environments. Their expansion is supported by shorter turnaround times, simpler workflows, CLIA-waived assays, and increasing assay availability.

The segment is strategically attractive because it combines instrument revenue with high-value proprietary cartridges. Respiratory disease currently represents the most visible use case, but STI testing, hepatitis, gastrointestinal disease, women’s health, and other infectious disease categories are expanding the addressable market.

Portable Coagulation, Hematology and Urinalysis Devices

This category includes INR and coagulation meters, compact hematology analyzers, portable cell-counting systems, urine analyzers, and related specialty devices. Coagulation testing has an established role in anticoagulation management, while urinalysis has broad primary-care and renal applications.

Portable hematology is an emerging opportunity. Advances in optics, microfluidics, imaging, and algorithmic cell classification could move selected hematology workflows into oncology practices, infusion settings, physician offices, rural facilities, and home-centered models.

By Technology

Electrochemical and Biosensor Technology

Electrochemical biosensors account for a substantial share of portable point-of-care testing because they underpin glucose, blood gas, electrolyte, lactate, and several metabolic measurements. The technology supports miniaturization, small sample volumes, rapid measurement, and relatively simple cartridge construction.

Future differentiation will increasingly come from sensor stability, calibration automation, interference management, multi-analyte capability, and data connectivity rather than the basic sensing principle alone.

Immunoassay and Fluorescence Technology

Immunoassay-based portable testing includes antigen, antibody, hormone, protein biomarker, inflammatory marker, and infectious disease applications. Fluorescence readers have increased the objectivity and sensitivity of rapid testing while allowing digital capture of results.

Manufacturers are moving toward compact, automated interpretation and broader multiplex capabilities. The technology will remain particularly relevant to urgent care and physician-office workflows where speed and operational simplicity are essential.

Molecular NAAT and PCR Technology

Molecular technology is expected to record the strongest growth within the technology segment. Portable PCR, RT-PCR, isothermal amplification, and other NAAT methods are reducing the traditional infrastructure requirement for molecular diagnostics.

The U.S. regulatory pipeline is increasingly populated with compact molecular systems designed specifically for decentralized use. Turnaround times below 20 minutes are becoming commercially important, especially for respiratory infections where treatment decisions may be made during the initial visit.

Microfluidic and Lab-on-Chip Technology

Microfluidics allows manufacturers to miniaturize sample handling, reagent mixing, separation, reaction, and detection into integrated cartridges. This architecture is central to the broader evolution toward “sample-in, answer-out” testing.

The commercial value is strongest when the cartridge eliminates manual pipetting, refrigeration, complex calibration, and multiple preparation steps. Microfluidic platforms are expected to play an expanding role in multi-analyte chemistry, immunoassay, molecular testing, coagulation, and hematology.

Optical, Photometric and Digital Imaging Technology

Optical and photometric technologies support urinalysis, hematology, immunoassays, and chemistry applications. New imaging sensors and computer-vision methods are expanding the ability of compact systems to interpret cells, strips, and reaction characteristics automatically.

The next growth cycle will be influenced by AI-assisted interpretation, improved optics, smartphone-class imaging components, and better algorithm validation.

By Application

Diabetes and Metabolic Disease Management

Diabetes and metabolic testing represent a major application area due to the scale and chronic nature of disease. Approximately 40 million Americans are estimated to have diabetes, creating recurring testing requirements throughout primary care, endocrinology, hospitals, pharmacies, community programs, and other settings.

Portable HbA1c, glucose, ketone, lipid, creatinine, and renal testing can support same-visit decisions and reduce dependence on external laboratory turnaround.

Infectious Disease Testing

Infectious disease is expected to be one of the fastest-growing applications through 2035. Respiratory infections remain the largest testing opportunity, but molecular platforms are extending decentralized diagnosis into STIs, hepatitis, pertussis, strep, and other conditions.

The commercial value of portable molecular testing is particularly high when immediate diagnosis changes treatment, limits unnecessary antibiotics, prevents loss to follow-up, or improves infection-control decisions.

Emergency and Critical Care Testing

Emergency and critical care applications include blood gases, electrolytes, lactate, glucose, hematocrit, cardiac-related biomarkers, coagulation, and renal measurements. Hospitals value these tests because turnaround time can directly affect triage, resuscitation, surgery, intensive care, and patient disposition.

Portable devices that produce multi-analyte results from a small specimen have an advantage because they reduce repeated sample collection and allow clinicians to act before centralized laboratory results become available.

Coagulation and Hematology

Portable coagulation supports anticoagulation clinics, perioperative assessment, cardiovascular care, and selected home or ambulatory workflows. Hematology is an emerging growth category as smaller analyzers gain analytical sophistication.

Demand will be driven by oncology monitoring, chronic disease care, anticoagulation management, and the opportunity to move selected testing closer to specialty practices.

Renal, Urinalysis, Women’s Health and Other Applications

This segment includes urinary tract assessment, albumin-to-creatinine ratio testing, renal function evaluation, pregnancy and fertility testing, selected reproductive health assays, and other near-patient diagnostics.

Renal testing has strong long-term potential because more than 35 million U.S. adults are estimated to have chronic kidney disease and many remain undiagnosed. Portable renal and urine testing can support earlier risk identification within primary care and diabetes management.

By End User

Hospitals and Emergency Departments

Hospitals represent the largest professional end-user group and accounted for an estimated USD 3.15 billion of the market in 2025. Emergency departments, intensive care units, operating rooms, neonatal units, cath labs, inpatient wards, and transport teams use portable testing where turnaround time has direct clinical value.

Large health systems increasingly manage point-of-care programs centrally, making connectivity, operator management, QC documentation, cybersecurity, and standardization critical procurement requirements.

Physician Offices, Urgent Care and Retail Clinics

This segment accounted for approximately USD 2.35 billion in 2025 and is expected to gain share. The United States has more than 15,000 urgent care centers, creating a large installed base for respiratory, strep, molecular, glucose, HbA1c, pregnancy, urinalysis, and other rapid testing technologies.

Same-visit diagnosis is the principal economic advantage. Platforms that allow the provider to test, diagnose, prescribe, and discharge within one encounter can materially improve workflow efficiency.

Ambulatory and Specialty Care Centers

Ambulatory surgery centers, oncology practices, anticoagulation clinics, dialysis-related services, infusion centers, specialty physician groups, and other outpatient facilities form an increasingly important customer base.

These sites generally prefer compact devices with limited maintenance and predictable consumable costs because they do not have the laboratory staffing or infrastructure available in hospitals.

EMS, Rural, Community and Mobile Health Settings

Portable testing is particularly well aligned with emergency medical services, rural hospitals, critical access facilities, community health programs, mobile clinics, correctional health, substance-use treatment settings, and public health outreach.

The market opportunity is smaller by revenue than hospitals or urgent care but strategically important because portability directly solves geographic and infrastructure constraints.

Home-Centered and Decentralized Care Providers

Professional home-health and decentralized care programs represent a developing end-user segment. Growth will depend on regulatory status, reimbursement, remote supervision models, and the ability to transmit results securely to clinicians.

The largest opportunity is likely to involve chronic disease monitoring, oncology-related hematology, anticoagulation, metabolic assessment, and hospital-at-home pathways where portable testing can prevent unnecessary facility visits.

Regional Insights: Where the Market is Growing Fastest

The U.S. Portable Point-of-Care Testing Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional demand differs substantially because portable testing adoption is influenced by population growth, chronic disease prevalence, hospital density, urgent care penetration, rurality, health system consolidation, clinical labor availability, payer mix, and access to advanced laboratory infrastructure.

The South is the largest regional market, while the West is expected to record the fastest CAGR through 2035. The Northeast remains a high-value, innovation-intensive region with sophisticated health systems and academic providers, while the Midwest offers stable hospital-based demand and significant opportunity in rural and community testing.

South

The South represented an estimated USD 3.36 billion in 2025, or approximately 38% of the U.S. portable point-of-care testing devices market. Under the forecast scenario, the region could reach approximately USD 8.58 billion by 2035, representing an estimated regional CAGR close to 9.8%.

The regional market includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Tennessee, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and West Virginia.

Texas is one of the most strategically important markets in the country. Its population exceeded 31 million in 2025, and its combination of Houston, Dallas-Fort Worth, Austin, San Antonio, large integrated health systems, extensive emergency networks, rural communities, and rapid population growth creates demand across nearly every portable testing category. Handheld blood analysis, respiratory molecular testing, diabetes testing, and urgent-care diagnostics have especially favorable demand conditions.

Florida, with more than 23 million residents, is another major market. Its older population supports substantial demand for diabetes, renal, coagulation, cardiometabolic, and acute-care testing. The state’s large urgent care footprint and geographically distributed senior population make decentralized testing particularly attractive.

North Carolina and Georgia each exceed 11 million residents and have experienced strong population growth. Charlotte, Raleigh-Durham, Atlanta, and surrounding suburban corridors are expanding outpatient and urgent-care infrastructure. North Carolina also benefits from a life-sciences ecosystem capable of supporting clinical validation and early technology adoption.

Virginia, Maryland, and Tennessee have attractive hospital and ambulatory markets. Maryland and Northern Virginia benefit from sophisticated provider networks and proximity to federal healthcare institutions, while Tennessee has major health system operators and a large healthcare services industry.

South Carolina is smaller but one of the faster-growing states by population, strengthening the long-term case for outpatient diagnostic capacity. Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, and West Virginia are particularly relevant to diabetes, renal disease, rural medicine, and community-based testing because chronic disease burden and healthcare-access limitations increase the value of portable diagnostics.

The South’s long-term advantage is therefore not simply population size. It combines rapid demographic expansion, large numbers of rural communities, substantial chronic disease burden, growing outpatient networks, and health-system investment. Manufacturers with scalable distribution, strong field service, easy-to-use CLIA-waived systems, and flexible contracting models are well positioned in this region.

West

The West accounted for approximately USD 1.93 billion in 2025 and is projected to become the fastest-growing region, potentially reaching USD 5.65 billion by 2035. This represents an estimated CAGR of approximately 11.3%, substantially above the national average.

The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii.

California is the dominant market, with approximately 39.4 million residents in 2025. The state combines an enormous patient population with academic medical centers, integrated delivery networks, venture-backed healthcare innovation, digital-health adoption, retail care, and major medtech activity. California health systems are attractive early adopters of connected diagnostics, molecular testing, AI-assisted platforms, and enterprise point-of-care informatics.

Arizona, Nevada, Utah, and Idaho are especially notable because of population growth. Arizona surpassed 7.6 million residents in 2025 and continues to add older adults, increasing demand for chronic disease and acute-care diagnostics. Nevada combines population growth with a distributed healthcare system and significant urgent-care demand.

Utah benefits from integrated health systems and a strong diagnostics and medtech ecosystem. Idaho remains a comparatively small market but its rapid growth and significant rural geography create favorable conditions for decentralized testing.

Washington and Oregon are important markets for connected care and integrated delivery networks. Seattle’s technology ecosystem supports adoption of digital health and interoperability solutions, while regional hospital systems place strong emphasis on standardized workflows and population health.

Colorado is one of the region’s strongest hospital and ambulatory markets and provides a useful bridge between metropolitan specialty care and rural testing needs. New Mexico, Montana, Wyoming, and Alaska have smaller absolute device markets but disproportionately strong use cases for portable diagnostics because geography and distance can make centralized laboratory access difficult. Hawaii similarly benefits from devices that can operate efficiently across distributed island-based healthcare networks.

The West is likely to gain national market share as portable diagnostics become increasingly software-driven, connected, AI-assisted, and compatible with nontraditional care models.

Northeast

The Northeast represented approximately USD 1.82 billion in 2025 and is projected to reach roughly USD 4.40 billion by 2035, equivalent to an estimated CAGR of about 9.2%.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, New Hampshire, Rhode Island, Vermont, and Delaware.

New York is the region’s largest state market, supported by a population of approximately 20 million, major academic health systems, dense physician networks, high emergency department volumes, and a sophisticated diagnostics infrastructure. The strongest demand is concentrated in hospital bedside testing, molecular diagnostics, outpatient networks, and large integrated health systems.

Pennsylvania has more than 13 million residents and combines major academic systems in Philadelphia and Pittsburgh with large rural areas. This creates a dual market: premium integrated point-of-care platforms for large hospital systems and practical decentralized diagnostics for community facilities.

New Jersey benefits from approximately 9.5 million residents, dense outpatient healthcare infrastructure, pharmaceutical and diagnostics industry concentration, and proximity to New York and Philadelphia healthcare ecosystems.

Massachusetts remains one of the most influential markets despite its smaller population. Boston’s academic hospitals, biotechnology ecosystem, clinical research activity, and specialist concentration make the state an important early-validation environment for emerging portable technologies.

Connecticut, Rhode Island, New Hampshire, Maine, Vermont, and Delaware are smaller revenue markets but have significant opportunities in community hospitals, physician-office testing, rural access, elder care, and outpatient networks.

Northeast procurement is typically evidence-intensive. Major health systems often require robust analytical validation, workflow documentation, cybersecurity assessment, interoperability, economic justification, and quality-system integration before enterprise deployment. This can lengthen sales cycles but creates durable contracts once a system is standardized.

Midwest

The Midwest accounted for approximately USD 1.64 billion in 2025 and is forecast to reach approximately USD 3.35 billion by 2035. The estimated CAGR of approximately 7.4% is below the national average but still reflects durable expansion.

The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota.

Illinois is the largest regional opportunity, supported by Chicago’s major academic centers, extensive health systems, urgent-care networks, and large population. Ohio is another major market with nearly 12 million residents and a high concentration of nationally recognized hospital systems and regional healthcare networks.

Michigan provides significant demand across diabetes, hospital bedside testing, emergency care, and community medicine. Minnesota has outsized strategic importance because of its medtech ecosystem, integrated delivery models, and sophisticated clinical infrastructure.

Indiana, Wisconsin, and Missouri provide strong mid-sized markets with large hospital networks and growing outpatient systems. Iowa, Kansas, Nebraska, North Dakota, and South Dakota have smaller absolute populations but meaningful need for rural and regional point-of-care deployment.

The Midwest’s commercial profile favors reliability and economic discipline. Buyers frequently prioritize service support, cartridge supply continuity, standardized contracts, low maintenance requirements, and total cost per test. Manufacturers that can demonstrate practical operational value rather than technology novelty alone are positioned to perform well.

Key Market Players

The U.S. Portable Point-of-Care Testing Devices competitive landscape is moderately consolidated in major established categories but increasingly fragmented in emerging molecular, hematology, microfluidic, and specialty diagnostic technologies.

Large diagnostics companies benefit from established hospital contracts, broad distribution, regulatory experience, extensive assay menus, and mature informatics infrastructure. Smaller innovators compete through faster molecular workflows, novel biosensors, microfluidics, simplified sample handling, AI-supported analysis, and specialized clinical use cases.

Some of the key participants relevant to the U.S. market include:

Abbott Laboratories / Abbott Point of Care
Roche Diagnostics
Siemens Healthineers
Danaher Corporation / Cepheid
QuidelOrtho Corporation
bioMérieux / BIOFIRE Diagnostics
Becton, Dickinson and Company
Nova Biomedical
Werfen
EKF Diagnostics
HemoCue
Sekisui Diagnostics
ACON Laboratories
PTS Diagnostics
ARKRAY
QIAGEN
Trinity Biotech
SD Biosensor
Sight Diagnostics
PixCell Medical
binx health
Visby Medical
Baebies
Commure / Athelas
Lumos Diagnostics

Abbott remains highly influential in handheld blood analysis, glucose-related testing, rapid diagnostics, and decentralized infectious disease testing. Roche has strengthened its point-of-care strategy through cobas liat molecular testing and the acquisition of LumiraDx’s point-of-care technology. Siemens Healthineers competes strongly in handheld blood gas, electrolyte, and metabolite testing through systems designed for critical-care workflows.

Danaher has an important position through Cepheid’s cartridge-based molecular testing and HemoCue’s portable diagnostic platforms. QuidelOrtho combines an established rapid immunoassay franchise with an expanding molecular strategy. bioMérieux is strengthening its decentralized molecular position through the BIOFIRE SPOTFIRE platform.

Competition over the next decade will shift increasingly toward installed-base economics. Vendors that place a multifunctional analyzer can generate recurring revenue as new assays are added. This makes assay-menu expansion, cartridge manufacturing scale, field service, distributor reach, and regulatory execution essential competitive capabilities.

Hospital contracts will also increasingly be influenced by data infrastructure. Buyers will favor suppliers able to provide device connectivity, QC monitoring, operator credentialing, cybersecurity support, middleware integration, and enterprise analytics.

Recent Developments

The recent development environment demonstrates how rapidly the U.S. portable point-of-care testing market is moving toward compact molecular testing, multifunctional platforms, CLIA-waived workflows, and strategic consolidation.

In June 2024, the FDA authorized the first point-of-care hepatitis C RNA test designed to enable molecular HCV detection in appropriately certified decentralized settings. The system can generate results in approximately an hour using a fingerstick blood specimen, strengthening the test-and-treat model for hepatitis C in settings such as physician offices, emergency departments, substance-use treatment facilities, and community programs.

In July 2024, Roche completed its acquisition of LumiraDx’s point-of-care technology. The transaction strengthened Roche’s decentralized diagnostic position across clinical chemistry, immunochemistry, coagulation, and molecular testing and illustrates the strategic importance larger diagnostics companies place on multi-assay portable platforms.

During 2024, additional CLIA-waived developments expanded portable HbA1c and urine-testing capabilities, reinforcing the movement of chronic disease testing into primary and decentralized care.

In January 2025, Roche received FDA clearance and CLIA waiver for cobas liat STI molecular assays designed to provide PCR results in approximately 20 minutes. The development is commercially important because same-visit STI diagnosis can reduce patient loss to follow-up and support more targeted treatment.

During 2025, additional cobas liat respiratory assays received CLIA-waived status, broadening the platform’s role in influenza, COVID-19, and RSV testing. Portable respiratory molecular testing remains one of the most competitive areas because urgent care and physician-office customers increasingly expect actionable results before the patient leaves.

In August 2025, the BIOFIRE SPOTFIRE Respiratory/Sore Throat Panel Mini received CLIA-waived status, expanding access to multiplex molecular testing across decentralized environments.

Abbott also received updated FDA clearance activity involving its i-STAT cartridge portfolio during 2025, highlighting the importance of ongoing regulatory management, labeling accuracy, sample-type validation, and post-market quality oversight even for mature point-of-care platforms.

In December 2025, Roche announced U.S. clearance and CLIA waiver for a cobas liat Bordetella molecular test capable of generating results in approximately 15 minutes. The expansion of compact PCR beyond core respiratory virus testing demonstrates how manufacturers are increasing the economic value of installed instruments through additional assay menus.

The competitive environment accelerated further in 2026. Nova received CLIA-waiver activity for an albumin-to-creatinine ratio assay on its portable Allegro platform, supporting decentralized renal disease screening.

In February 2026, the LEX VELO molecular system received FDA clearance and CLIA-waived status for rapid respiratory molecular testing, with results designed to be generated in approximately six to ten minutes. QuidelOrtho completed its acquisition of LEX Diagnostics in April 2026 for approximately USD 100 million, strengthening its strategic position in ultra-fast molecular point-of-care diagnostics.

In March 2026, Baebies received FDA clearance and CLIA-waiver approval for a respiratory molecular assay on its FINDER platform. The platform’s broader development strategy is important because multifunctional portable systems capable of supporting molecular, chemistry, coagulation, or immunoassay workflows could create a new competitive class within decentralized diagnostics.

Also in March 2026, the FebriDx bacterial/non-bacterial respiratory assay received CLIA-waived status, illustrating demand for tests that help clinicians distinguish whether an acute respiratory illness is more consistent with a bacterial or non-bacterial response.

In 2026, AI-enabled hematology also moved further into point-of-care use, signaling a possible new growth frontier for compact cell-analysis platforms. If accuracy, reimbursement, workflow integration, and cost improve sufficiently, hematology could become one of the more disruptive portable diagnostic categories during the next decade.

These developments collectively show that the market is moving from basic rapid testing toward portable laboratory functionality. The competitive question is increasingly not whether a test can be decentralized, but how many clinically valuable assays can be delivered quickly, safely, and economically from a compact platform.

Conclusion

The U.S. Portable Point-of-Care Testing Devices Market Size & Share is positioned for strong long-term expansion from approximately USD 8.75 billion in 2025 to USD 21.98 billion by 2035, representing a 9.65% CAGR during 2026–2035.

Market growth will be driven by the decentralization of healthcare, high chronic disease burden, rapid molecular innovation, expansion of urgent care, growing CLIA-waived test menus, rural diagnostic needs, hospital labor pressure, and increasing demand for same-visit clinical decision-making.

The most attractive growth opportunities will emerge in portable molecular diagnostics, multi-analyte blood chemistry, connected metabolic testing, microfluidic platforms, AI-enabled hematology, multiplex infectious disease testing, renal disease screening, and digitally managed enterprise point-of-care programs.

Portable molecular testing is likely to produce the strongest percentage growth as PCR-quality diagnostics become faster, simpler, and accessible to more decentralized settings. Blood chemistry and glucose-related testing will remain substantial revenue categories because of established clinical demand and recurring consumable usage.

Hospitals will remain the largest institutional purchasers, but physician offices, urgent care networks, retail clinics, specialty ambulatory centers, rural providers, and decentralized care programs will capture a rising proportion of incremental demand. This shift will reward devices that require minimal laboratory infrastructure and limited specialized training.

Geographically, the South will remain the largest regional opportunity, supported by Texas, Florida, North Carolina, Georgia, Virginia, Tennessee, and other high-growth or high-disease-burden states. The West is expected to record the fastest growth, led by California and strengthened by population expansion in Arizona, Nevada, Utah, Idaho, and Washington. The Northeast will remain a premium technology-adoption market, while the Midwest will provide durable hospital and rural-testing demand.

For manufacturers, market leadership will increasingly depend on five interdependent capabilities: clinically differentiated test menus, rapid and reliable analytical performance, scalable consumables economics, enterprise-grade connectivity, and regulatory execution.

For hospitals and healthcare buyers, the central purchasing question will move beyond whether a portable test is faster than a central laboratory. Buyers will increasingly ask whether the platform changes the economics of the patient encounter. Devices that shorten time to treatment, reduce repeat visits, support faster patient disposition, eliminate manual result entry, simplify decentralized quality management, and consolidate multiple tests onto one platform will command the strongest strategic value.

For investors and strategic entrants, the market’s highest-value opportunities are likely to exist where portability solves a real clinical bottleneck rather than simply miniaturizing an existing laboratory process. Ultra-fast molecular testing, multifunctional cartridges, fingerstick diagnostics, portable renal screening, AI-supported cell analysis, and cloud-connected platforms are particularly well positioned.

The next decade of U.S. portable point-of-care testing will therefore be defined by the progressive compression of laboratory capability into increasingly small, automated, connected devices. Companies that combine laboratory-grade performance with near-patient simplicity and demonstrable workflow economics will be best positioned to define the competitive landscape through 2035.

TABLE OF CONTENT

1. U.S. Portable Point-of-Care Testing Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.2.1. Portable Point-of-Care Testing Devices Included in the Study
1.2.2. Dedicated Reagents, Cartridges, Test Cards and Consumables Included in the Study
1.2.3. Products and Diagnostic Categories Excluded from the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Bottom-Up Market Sizing Methodology
1.3.6. Top-Down Market Validation Methodology
1.3.7. Analytical Frameworks & Forecasting Models
1.3.8. Data Triangulation, Validation and Final Report Publishing
1.4. Key Assumptions
1.4.1. Historical Period, 2021–2024
1.4.2. Base Year, 2025
1.4.3. Forecast Period, 2026–2035
1.4.4. Currency and Revenue Recognition Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Point-of-Care Diagnostic Device Manufacturers
1.6.2. Assay, Cartridge, Reagent and Biosensor Suppliers
1.6.3. Component and Contract Manufacturing Organizations
1.6.4. Hospitals and Integrated Delivery Networks
1.6.5. Physician Offices and Urgent Care Networks
1.6.6. Retail Clinics and Community Health Providers
1.6.7. Ambulatory and Specialty Care Providers
1.6.8. Group Purchasing Organizations and Medical Distributors
1.6.9. Clinical Laboratories and Point-of-Care Coordinators
1.6.10. Payers, CMS, FDA, CLIA Regulators and Clinical Decision-Makers

What this section provides: This section defines the precise boundary of the U.S. portable point-of-care testing devices market, the products and consumables included, historical and forecast periods, market-sizing methodology, assumptions, and stakeholder ecosystem used to measure and validate the market.

2. U.S. Portable Point-of-Care Testing Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.5.1. U.S. Market Size, 2025
2.5.2. Leading Product Category, 2025
2.5.3. Fastest-Growing Technology Category
2.5.4. Largest End-User Segment
2.5.5. Leading U.S. Region
2.6. Forecast Outlook, 2026–2035
2.6.1. Market Size Forecast, 2026–2035
2.6.2. CAGR Analysis, 2026–2035
2.7. High-Growth Opportunity Areas
2.7.1. Ultra-Fast Molecular Point-of-Care Testing
2.7.2. Multiplex Infectious Disease Diagnostics
2.7.3. Connected Handheld Blood Analysis
2.7.4. Portable HbA1c and Renal Screening
2.7.5. AI-Enabled Portable Hematology
2.7.6. Decentralized and Home-Centered Diagnostics

What this section provides: This section gives decision-makers an executive view of market size, historical performance, forecast growth, high-growth technologies, leading customer groups, regional opportunities, and the most commercially attractive segments through 2035.

3. U.S. Portable Point-of-Care Testing Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Decentralization of Diagnostic Testing Across U.S. Healthcare
3.1.2. Increasing U.S. Diabetes and Cardiometabolic Disease Burden
3.1.3. Growing Demand for Rapid Infectious Disease Diagnosis
3.1.4. Expansion of Urgent Care and Convenient-Care Networks
3.1.5. Hospital Demand for Faster Clinical Decision-Making
3.1.6. Growth in CLIA-Waived Diagnostic Testing
3.1.7. Rural and Underserved Healthcare Access Requirements
3.1.8. Increasing Adoption of Connected Point-of-Care Devices
3.1.9. Rising Demand for Same-Visit Diagnosis and Treatment
3.2. Restraints and Their Impact Analysis
3.2.1. Higher Per-Test Cost Compared with Central Laboratory Testing
3.2.2. Quality-Control and Operator Competency Requirements
3.2.3. Reimbursement Variability Across Point-of-Care Tests
3.2.4. Laboratory Oversight and Governance Complexity
3.2.5. Device Connectivity and Cybersecurity Requirements
3.2.6. Product Recall and Diagnostic Accuracy Risk
3.3. Opportunities and Their Impact Analysis
3.3.1. Portable Molecular Testing Beyond Respiratory Diseases
3.3.2. Multiplex and Syndromic Panel Expansion
3.3.3. Portable Renal Disease and Metabolic Screening
3.3.4. AI-Enabled Hematology and Digital Cell Analysis
3.3.5. Emergency Medical Services and Pre-Hospital Testing
3.3.6. Rural Health and Community Testing Expansion
3.3.7. Hospital-at-Home and Decentralized Care Programs
3.3.8. Multi-Assay Platform and Recurring Cartridge Models
3.4. Challenges and Their Impact Analysis
3.4.1. Maintaining Central-Laboratory-Equivalent Analytical Performance
3.4.2. Managing Large Distributed Device Fleets
3.4.3. Training Non-Laboratory Operators
3.4.4. Cartridge and Reagent Supply Continuity
3.4.5. Demonstrating Clinical and Economic Utility
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Clinical Workflow Economics Analysis
3.6.1. Turnaround-Time Economics
3.6.2. Emergency Department Throughput Impact
3.6.3. Same-Visit Treatment Economics
3.6.4. Laboratory Labor and Specimen Transport Economics
3.7. Hospital and Health System Procurement Behavior Analysis
3.7.1. Cost-per-Reportable-Result Assessment
3.7.2. Analyzer Placement and Reagent-Rental Models
3.7.3. Enterprise Standardization Decisions
3.7.4. Point-of-Care Connectivity Requirements

What this section provides: This section evaluates the clinical, economic, technological, regulatory, reimbursement, and operational forces shaping portable POC testing demand and identifies the principal upside opportunities and commercialization risks.

4. U.S. Portable Point-of-Care Testing Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.3.1. Analyzer Pricing Trends
4.3.2. Cartridge and Consumables Pricing Trends
4.3.3. Reagent-Rental and Instrument Placement Models
4.4. Value Chain & Supply Chain Analysis
4.4.1. Raw Materials and Diagnostic Components
4.4.2. Biosensors, Microfluidics and Optical Components
4.4.3. Assay and Cartridge Manufacturing
4.4.4. Device Assembly and Quality Control
4.4.5. Distribution and Healthcare Delivery Channels
4.5. Impact of Digitalization and Connected Diagnostics
4.5.1. LIS and EHR Connectivity
4.5.2. Cloud-Based Device Management
4.5.3. Remote Quality-Control Monitoring
4.5.4. Operator Credentialing and Device Governance
4.6. Application & Innovation Landscape
4.7. FDA Regulatory Framework Analysis
4.7.1. 510(k) Pathway
4.7.2. De Novo Classification
4.7.3. Premarket Approval Considerations
4.7.4. Emergency and Special Regulatory Pathways
4.8. CLIA Regulatory and Waiver Landscape
4.8.1. CLIA-Waived Tests
4.8.2. Moderate-Complexity Testing
4.8.3. Laboratory-Developed and Professional Oversight Considerations
4.9. CMS Reimbursement and Coverage Landscape
4.9.1. CPT and HCPCS Considerations
4.9.2. Medicare Clinical Laboratory Fee Schedule
4.9.3. Physician Office and Urgent Care Reimbursement
4.10. Import/Export Restrictions & Tariff Impact
4.11. Government Initiatives and Public Health Programs
4.12. Impact of Escalating Geopolitical Tensions
4.13. Health System Value Analysis Committee Decision Framework
4.14. Point-of-Care Testing Governance and Compliance Framework

What this section provides: This section gives clients a comprehensive view of regulation, CLIA status, reimbursement, pricing, supply chain, digital integration, competitive forces, device governance, and healthcare procurement conditions affecting U.S. portable point-of-care testing.

5. U.S. Portable Point-of-Care Testing Devices Market – By Product Type

5.1. Overview
5.1.1. Segment Share Analysis, By Product Type, 2025 & 2035 (%)
5.1.2. Handheld Blood Chemistry and Blood Gas Analyzers
5.1.2.1. Blood Gas Analyzers
5.1.2.2. Electrolyte Analyzers
5.1.2.3. Lactate Testing Systems
5.1.2.4. Creatinine and Renal Function Analyzers
5.1.2.5. Multi-Analyte Blood Chemistry Systems
5.1.3. Portable Glucose, HbA1c and Metabolic Testing Systems
5.1.3.1. Professional Blood Glucose Meters
5.1.3.2. Portable HbA1c Analyzers
5.1.3.3. Ketone Testing Devices
5.1.3.4. Lipid Testing Systems
5.1.3.5. Multi-Parameter Metabolic Analyzers
5.1.4. Portable Immunoassay and Rapid-Test Readers
5.1.4.1. Fluorescence Immunoassay Readers
5.1.4.2. Digital Lateral Flow Readers
5.1.4.3. Cardiac Biomarker Testing Systems
5.1.4.4. Infectious Disease Rapid-Test Readers
5.1.4.5. Hormonal and Specialty Immunoassay Systems
5.1.5. Portable Molecular Diagnostic Systems
5.1.5.1. Portable PCR Systems
5.1.5.2. RT-PCR Systems
5.1.5.3. Isothermal Nucleic Acid Amplification Systems
5.1.5.4. Multiplex Molecular Diagnostic Platforms
5.1.5.5. Ultra-Rapid Molecular Testing Systems
5.1.6. Portable Coagulation, Hematology and Urinalysis Devices
5.1.6.1. Portable INR and Coagulation Meters
5.1.6.2. Compact Hematology Analyzers
5.1.6.3. AI-Enabled Digital Hematology Systems
5.1.6.4. Portable Urinalysis Analyzers
5.1.6.5. Specialty Portable Diagnostic Devices

What this section provides: This section identifies the portable diagnostic device categories generating the greatest revenue, recurring consumable demand, installed-base opportunity, and growth potential through 2035.

6. U.S. Portable Point-of-Care Testing Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Diabetes and Metabolic Disease Management
6.1.2.1. Blood Glucose Assessment
6.1.2.2. HbA1c Monitoring
6.1.2.3. Ketone Testing
6.1.2.4. Lipid and Cardiometabolic Testing
6.1.2.5. Renal Risk Monitoring in Diabetes
6.1.3. Infectious Disease Testing
6.1.3.1. Respiratory Infection Testing
6.1.3.2. Influenza Testing
6.1.3.3. COVID-19 Testing
6.1.3.4. RSV Testing
6.1.3.5. Streptococcal Infection Testing
6.1.3.6. Sexually Transmitted Infection Testing
6.1.3.7. Hepatitis and Other Infectious Disease Testing
6.1.4. Emergency and Critical Care Testing
6.1.4.1. Blood Gas Testing
6.1.4.2. Electrolyte Testing
6.1.4.3. Lactate and Sepsis-Related Testing
6.1.4.4. Cardiac Biomarker Assessment
6.1.4.5. Acute Renal and Metabolic Assessment
6.1.5. Coagulation and Hematology
6.1.5.1. PT/INR Testing
6.1.5.2. Anticoagulation Monitoring
6.1.5.3. Complete Blood Count and Cell Analysis
6.1.5.4. Oncology and Infusion Monitoring
6.1.6. Renal, Urinalysis, Women’s Health and Other Applications
6.1.6.1. Chronic Kidney Disease Screening
6.1.6.2. Albumin-to-Creatinine Ratio Testing
6.1.6.3. Urinary Tract Assessment
6.1.6.4. Pregnancy Testing
6.1.6.5. Fertility and Reproductive Health Testing
6.1.6.6. Other Point-of-Care Applications

What this section provides: This section evaluates portable POC demand by clinical use case and highlights applications where rapid results have the greatest impact on treatment decisions, patient flow, diagnostic access, and recurring test utilization.

7. U.S. Portable Point-of-Care Testing Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Hospitals and Emergency Departments
7.1.2.1. Emergency Departments
7.1.2.2. Intensive Care Units
7.1.2.3. Operating Rooms and Perioperative Care
7.1.2.4. Inpatient Wards
7.1.2.5. Neonatal and Pediatric Units
7.1.3. Physician Offices, Urgent Care and Retail Clinics
7.1.3.1. Primary Care Practices
7.1.3.2. Urgent Care Centers
7.1.3.3. Retail Health Clinics
7.1.3.4. Family Medicine and Internal Medicine Practices
7.1.4. Ambulatory and Specialty Care Centers
7.1.4.1. Ambulatory Surgery Centers
7.1.4.2. Oncology and Infusion Centers
7.1.4.3. Anticoagulation Clinics
7.1.4.4. Diabetes and Endocrinology Clinics
7.1.4.5. Dialysis and Renal Care Centers
7.1.5. EMS, Rural, Community and Mobile Health Settings
7.1.5.1. Emergency Medical Services
7.1.5.2. Critical Access Hospitals
7.1.5.3. Federally Qualified Health Centers
7.1.5.4. Rural Health Clinics
7.1.5.5. Mobile Diagnostic and Public Health Units
7.1.6. Home-Centered and Decentralized Care Providers
7.1.6.1. Home Healthcare Organizations
7.1.6.2. Hospital-at-Home Programs
7.1.6.3. Remote Chronic Disease Management Providers
7.1.6.4. Decentralized Clinical Care Networks

What this section provides: This section explains which U.S. care environments generate the strongest analyzer and consumables demand and how purchasing priorities differ across hospitals, urgent care, physician offices, specialty centers, rural providers, EMS, and home-centered care.

8. U.S. Portable Point-of-Care Testing Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Electrochemical and Biosensor Technology
8.1.2.1. Amperometric Sensors
8.1.2.2. Potentiometric Sensors
8.1.2.3. Enzymatic Biosensors
8.1.2.4. Multi-Analyte Electrochemical Sensors
8.1.3. Immunoassay and Fluorescence Technology
8.1.3.1. Lateral Flow Immunoassay
8.1.3.2. Fluorescence Immunoassay
8.1.3.3. Enzyme-Based Immunoassay
8.1.3.4. Digital Immunoassay Interpretation
8.1.4. Molecular NAAT and PCR Technology
8.1.4.1. PCR
8.1.4.2. RT-PCR
8.1.4.3. Isothermal Amplification
8.1.4.4. Multiplex Nucleic Acid Testing
8.1.4.5. Ultra-Fast Molecular Amplification
8.1.5. Microfluidic and Lab-on-Chip Technology
8.1.5.1. Cartridge-Based Microfluidics
8.1.5.2. Centrifugal Microfluidics
8.1.5.3. Capillary Microfluidics
8.1.5.4. Sample-to-Answer Integrated Systems
8.1.6. Optical, Photometric and Digital Imaging Technology
8.1.6.1. Reflectance Photometry
8.1.6.2. Spectrophotometric Detection
8.1.6.3. Digital Microscopy
8.1.6.4. Computer Vision and AI-Assisted Analysis

What this section provides: This section evaluates the sensing, molecular, microfluidic, optical, and AI-enabled technologies shaping portable diagnostic performance, turnaround time, miniaturization, assay expansion, and future product differentiation.

9. U.S. Portable Point-of-Care Testing Devices Market – By Procurement Channel

9.1. Overview
9.1.1. Segment Share Analysis, By Procurement Channel, 2025 & 2035 (%)
9.1.2. Direct Hospital and Health System Procurement
9.1.2.1. Capital Purchase
9.1.2.2. Reagent-Rental Agreements
9.1.2.3. Analyzer Placement Contracts
9.1.3. Integrated Delivery Network Enterprise Contracts
9.1.3.1. Multi-Hospital Standardization Agreements
9.1.3.2. Enterprise Point-of-Care Platform Contracts
9.1.3.3. System-Wide Consumables Agreements
9.1.4. Group Purchasing Organization Contracts
9.1.4.1. National GPO Agreements
9.1.4.2. Regional GPO Agreements
9.1.4.3. Aggregated Purchasing Programs
9.1.5. Distributor and Specialty Supplier Sales
9.1.5.1. National Medical Distributors
9.1.5.2. Regional Diagnostic Distributors
9.1.5.3. Specialty Laboratory and Physician-Office Suppliers
9.1.6. Ambulatory, Office-Based and Decentralized Care Procurement
9.1.6.1. Physician Office Purchasing
9.1.6.2. Urgent Care Network Purchasing
9.1.6.3. Retail Clinic Purchasing
9.1.6.4. Community and Rural Provider Purchasing
9.1.6.5. Home-Centered Care Procurement

What this section provides: This section explains how portable point-of-care devices, cartridges, and reagents are purchased across the U.S., including direct contracting, IDN standardization, GPO influence, reagent-rental models, distribution channels, and decentralized-site procurement.

10. U.S. Portable Point-of-Care Testing Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Point-of-Care Testing Volume and Healthcare Infrastructure Analysis
10.1.4. Regional CLIA-Waived Testing and Decentralized Diagnostic Adoption
10.1.5. Regional Reimbursement and Procurement Dynamics
10.1.6. Regional Chronic Disease and Infectious Disease Demand Analysis
10.1.7. Regional Urgent Care, Rural Health and Ambulatory Testing Landscape

10.2. West Region

10.2.1. Regional Overview & Trends
10.2.2. West Region Portable Point-of-Care Testing Device Key Manufacturers and Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3. Northeast Region

10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Portable Point-of-Care Testing Device Key Manufacturers and Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4. South Region

10.4.1. Regional Overview & Trends
10.4.2. South Region Portable Point-of-Care Testing Device Key Manufacturers and Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5. Midwest Region

10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Portable Point-of-Care Testing Device Key Manufacturers and Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Type, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Market Size and Forecast, By Procurement Channel, 2021–2035 (US$ Billion)

What this section provides: This section delivers comprehensive four-region and 50-state analysis, enabling clients to identify geographic demand concentration, decentralized diagnostic adoption hotspots, hospital and urgent-care testing hubs, rural access opportunities, procurement differences, and state-level commercial priorities.

11. U.S. Portable Point-of-Care Testing Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.1.1. Market Share by Major Company
11.1.2. Market Concentration Analysis
11.1.3. Installed-Base and Recurring Consumables Positioning
11.2. Company Positioning Matrix
11.2.1. Leaders
11.2.2. Challengers
11.2.3. Innovators
11.2.4. Emerging Players
11.3. Competitive Benchmarking
11.3.1. Product Portfolio Breadth
11.3.2. Portable Molecular Testing Capability
11.3.3. CLIA-Waived Assay Portfolio
11.3.4. Instrument Installed Base
11.3.5. Cartridge and Consumables Revenue Model
11.3.6. Connectivity and Informatics Capability
11.3.7. Hospital and Alternate-Site Channel Strength
11.4. Company Profiles
11.4.1. Abbott Laboratories / Abbott Point of Care
11.4.2. Roche Diagnostics
11.4.3. Siemens Healthineers
11.4.4. Danaher Corporation / Cepheid
11.4.5. QuidelOrtho Corporation
11.4.6. bioMérieux / BIOFIRE Diagnostics
11.4.7. Becton, Dickinson and Company
11.4.8. Nova Biomedical
11.4.9. Werfen
11.4.10. EKF Diagnostics
11.4.11. HemoCue
11.4.12. Sekisui Diagnostics
11.4.13. ACON Laboratories
11.4.14. PTS Diagnostics
11.4.15. ARKRAY
11.4.16. QIAGEN
11.4.17. Trinity Biotech
11.4.18. SD Biosensor
11.4.19. Sight Diagnostics
11.4.20. PixCell Medical
11.4.21. binx health
11.4.22. Visby Medical
11.4.23. Baebies
11.4.24. OraSure Technologies
11.4.25. Lumos Diagnostics

Note: Each company profile will include company overview, portable point-of-care testing portfolio, major platforms and assays, U.S. market strategy, CLIA-waived presence, FDA regulatory updates, installed-base strategy, partnerships, acquisitions, competitive positioning, and recent developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, platform positioning, assay-menu comparison, installed-base economics, connectivity capabilities, regulatory progress, and strategic intelligence on major U.S. portable POC testing companies.

12. U.S. Portable Point-of-Care Testing Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. Ultra-Fast Molecular Point-of-Care Testing
12.2.2. Multiplex and Syndromic Diagnostic Platforms
12.2.3. AI-Enabled Hematology and Digital Microscopy
12.2.4. Microfluidic Sample-to-Answer Systems
12.2.5. Connected and Cloud-Managed POC Diagnostics
12.2.6. Low-Volume Fingerstick and Capillary Sampling Platforms
12.3. Future CLIA-Waived Testing Landscape
12.4. Evolution of Portable Multi-Assay Diagnostic Platforms
12.5. Emerging Business Trends
12.5.1. Instrument Placement and Recurring Cartridge Economics
12.5.2. Platform Consolidation Across Health Systems
12.5.3. Decentralized Molecular Testing Expansion
12.5.4. Retail, Rural and Community Diagnostics
12.5.5. Hospital-at-Home Diagnostic Integration
12.6. Business Opportunities for Startups and Existing Players
12.7. Investment Prioritization Matrix
12.7.1. High-Growth / High-Attractiveness Segments
12.7.2. Emerging Technology Opportunities
12.7.3. Underserved Clinical Applications
12.7.4. Priority U.S. States and Regional Markets

What this section provides: This section prepares clients for technology disruption, CLIA-waived assay expansion, changes in competitive structure, future testing-site migration, investment opportunities, and alternative market-growth scenarios through 2035.

13. U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations

13.1. Recommendations for Point-of-Care Device Manufacturers
13.1.1. Portfolio and Assay-Menu Expansion
13.1.2. CLIA-Waiver Strategy
13.1.3. Cartridge and Consumables Strategy
13.1.4. Connectivity and Informatics Strategy
13.2. Recommendations for Hospitals and Health Systems
13.2.1. Platform Standardization
13.2.2. Cost-per-Result Optimization
13.2.3. Device Fleet Governance
13.2.4. Point-of-Care Quality Management
13.3. Recommendations for Physician Office and Urgent Care Networks
13.4. Recommendations for Investors and Private Equity Firms
13.5. Recommendations for Distributors and Channel Partners
13.6. Recommendations for New Entrants and Startups
13.7. Go-to-Market Strategy Considerations
13.7.1. Hospital and IDN Strategy
13.7.2. Urgent Care and Physician Office Strategy
13.7.3. Rural and Community Health Strategy
13.7.4. Distributor-Led Market Entry
13.8. Product Positioning and Portfolio Expansion Guidance
13.9. State-Level Commercial Prioritization Strategy
13.10. Partnership, Licensing and M&A Opportunity Assessment

What this section provides: This section converts the market intelligence into actionable recommendations for manufacturers, health systems, urgent-care operators, investors, distributors, and new entrants across product positioning, regulatory strategy, portfolio expansion, channel development, and geographic prioritization.

14. U.S. Portable Point-of-Care Testing Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Sizing Limitation
14.4. Forecasting Limitation
14.5. Regulatory and Reimbursement Information Limitation
14.6. Legal Disclaimer
14.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s market boundaries, data-use conditions, estimation and forecasting limitations, regulatory and reimbursement caveats, legal boundaries, and treatment of third-party information.

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Portable Point-of-Care Testing Devices Market: Market Definition and Scope
TABLE 3: U.S. Portable Point-of-Care Testing Devices Market: Research Methodology Framework
TABLE 4: U.S. Portable Point-of-Care Testing Devices Market: Key Assumptions
TABLE 5: U.S. Portable Point-of-Care Testing Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Portable Point-of-Care Testing Devices Market: Stakeholder Analysis
TABLE 7: U.S. Portable Point-of-Care Testing Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Portable Point-of-Care Testing Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Portable Point-of-Care Testing Devices Market: Market Attractiveness Index
TABLE 10: U.S. Portable Point-of-Care Testing Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Portable Point-of-Care Testing Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Portable Point-of-Care Testing Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Portable Point-of-Care Testing Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 14: U.S. Portable Point-of-Care Testing Devices Market: Drivers; Impact Analysis
TABLE 15: U.S. Portable Point-of-Care Testing Devices Market: Restraints; Impact Analysis
TABLE 16: U.S. Portable Point-of-Care Testing Devices Market: Opportunities; Impact Analysis
TABLE 17: U.S. Portable Point-of-Care Testing Devices Market: Challenges; Impact Analysis
TABLE 18: U.S. Portable Point-of-Care Testing Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 19: U.S. Portable Point-of-Care Testing Devices Market: Clinical Workflow Economics Matrix
TABLE 20: U.S. Portable Point-of-Care Testing Devices Market: Hospital and Health System Procurement Behavior Matrix
TABLE 21: U.S. Portable Point-of-Care Testing Devices Market: PESTEL Analysis
TABLE 22: U.S. Portable Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
TABLE 23: U.S. Portable Point-of-Care Testing Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 24: U.S. Portable Point-of-Care Testing Devices Market: Value Chain Analysis
TABLE 25: U.S. Portable Point-of-Care Testing Devices Market: Supply Chain Analysis
TABLE 26: U.S. Portable Point-of-Care Testing Devices Market: Digitalization and Connected Diagnostics Impact
TABLE 27: U.S. Portable Point-of-Care Testing Devices Market: FDA Regulatory Framework Analysis
TABLE 28: U.S. Portable Point-of-Care Testing Devices Market: CLIA Regulatory and Waiver Landscape
TABLE 29: U.S. Portable Point-of-Care Testing Devices Market: CMS Reimbursement and Coverage Landscape
TABLE 30: U.S. Portable Point-of-Care Testing Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 31: U.S. Portable Point-of-Care Testing Devices Market: Government Initiatives and Public Health Programs
TABLE 32: U.S. Portable Point-of-Care Testing Devices Market: Impact of Escalating Geopolitical Tensions
TABLE 33: U.S. Portable Point-of-Care Testing Devices Market: Health System Value Analysis Committee Decision Framework
TABLE 34: U.S. Portable Point-of-Care Testing Devices Market: Point-of-Care Testing Governance and Compliance Framework
TABLE 35: U.S. Portable Point-of-Care Testing Devices Market: Product Type Snapshot, 2025
TABLE 36: Segment Dashboard; Definition and Scope, by Product Type
TABLE 37: U.S. Portable Point-of-Care Testing Devices Market, by Product Type, 2021–2035 (US$ Billion)
TABLE 38: U.S. Portable Point-of-Care Testing Devices Market: Segment Share Analysis, by Product Type, 2025 & 2035 (%)
TABLE 39: U.S. Portable Point-of-Care Testing Devices Market: Handheld Blood Chemistry and Blood Gas Analyzers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 40: U.S. Portable Point-of-Care Testing Devices Market: Portable Glucose, HbA1c and Metabolic Testing Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 41: U.S. Portable Point-of-Care Testing Devices Market: Portable Immunoassay and Rapid-Test Readers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 42: U.S. Portable Point-of-Care Testing Devices Market: Portable Molecular Diagnostic Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 43: U.S. Portable Point-of-Care Testing Devices Market: Portable Coagulation, Hematology and Urinalysis Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 44: U.S. Portable Point-of-Care Testing Devices Market: Application Snapshot, 2025
TABLE 45: Segment Dashboard; Definition and Scope, by Application
TABLE 46: U.S. Portable Point-of-Care Testing Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 47: U.S. Portable Point-of-Care Testing Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 48: U.S. Portable Point-of-Care Testing Devices Market: Diabetes and Metabolic Disease Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: U.S. Portable Point-of-Care Testing Devices Market: Infectious Disease Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Portable Point-of-Care Testing Devices Market: Emergency and Critical Care Testing Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Portable Point-of-Care Testing Devices Market: Coagulation and Hematology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Portable Point-of-Care Testing Devices Market: Renal, Urinalysis, Women’s Health and Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Portable Point-of-Care Testing Devices Market: End User Snapshot, 2025
TABLE 54: Segment Dashboard; Definition and Scope, by End User
TABLE 55: U.S. Portable Point-of-Care Testing Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 56: U.S. Portable Point-of-Care Testing Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 57: U.S. Portable Point-of-Care Testing Devices Market: Hospitals and Emergency Departments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 58: U.S. Portable Point-of-Care Testing Devices Market: Physician Offices, Urgent Care and Retail Clinics Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Portable Point-of-Care Testing Devices Market: Ambulatory and Specialty Care Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Portable Point-of-Care Testing Devices Market: EMS, Rural, Community and Mobile Health Settings Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Portable Point-of-Care Testing Devices Market: Home-Centered and Decentralized Care Providers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Portable Point-of-Care Testing Devices Market: Technology Type Snapshot, 2025
TABLE 63: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 64: U.S. Portable Point-of-Care Testing Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 65: U.S. Portable Point-of-Care Testing Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 66: U.S. Portable Point-of-Care Testing Devices Market: Electrochemical and Biosensor Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 67: U.S. Portable Point-of-Care Testing Devices Market: Immunoassay and Fluorescence Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Portable Point-of-Care Testing Devices Market: Molecular NAAT and PCR Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Portable Point-of-Care Testing Devices Market: Microfluidic and Lab-on-Chip Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Portable Point-of-Care Testing Devices Market: Optical, Photometric and Digital Imaging Technology Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Portable Point-of-Care Testing Devices Market: Procurement Channel Snapshot, 2025
TABLE 72: Segment Dashboard; Definition and Scope, by Procurement Channel
TABLE 73: U.S. Portable Point-of-Care Testing Devices Market, by Procurement Channel, 2021–2035 (US$ Billion)
TABLE 74: U.S. Portable Point-of-Care Testing Devices Market: Segment Share Analysis, by Procurement Channel, 2025 & 2035 (%)
TABLE 75: U.S. Portable Point-of-Care Testing Devices Market: Direct Hospital and Health System Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 76: U.S. Portable Point-of-Care Testing Devices Market: Integrated Delivery Network Enterprise Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Portable Point-of-Care Testing Devices Market: Group Purchasing Organization Contracts Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Portable Point-of-Care Testing Devices Market: Distributor and Specialty Supplier Sales Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Portable Point-of-Care Testing Devices Market: Ambulatory, Office-Based and Decentralized Care Procurement Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Portable Point-of-Care Testing Devices Market: Regional Snapshot, 2025
TABLE 81: Segment Dashboard; Definition and Scope, by Region
TABLE 82: U.S. Portable Point-of-Care Testing Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 83: U.S. Portable Point-of-Care Testing Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 84: West Region U.S. Portable Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 85: West Region U.S. Portable Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 86: West Region U.S. Portable Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 87: West Region U.S. Portable Point-of-Care Testing Devices Market: Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 88: California Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 89: Washington Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 90: Arizona Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 91: Colorado Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 92: Oregon Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 93: Utah Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 94: Nevada Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 95: New Mexico Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 96: Idaho Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 97: Montana Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 98: Wyoming Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 99: Alaska Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 100: Hawaii Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 101: Northeast Region U.S. Portable Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 102: Northeast Region U.S. Portable Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 103: Northeast Region U.S. Portable Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 104: Northeast Region U.S. Portable Point-of-Care Testing Devices Market: Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 105: New York Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 106: Massachusetts Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 107: New Jersey Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 108: Pennsylvania Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 109: Connecticut Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 110: Maine Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 111: Vermont Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 112: New Hampshire Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 113: Rhode Island Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 114: Delaware Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 115: South Region U.S. Portable Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 116: South Region U.S. Portable Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 117: South Region U.S. Portable Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 118: South Region U.S. Portable Point-of-Care Testing Devices Market: Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 119: Texas Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 120: Florida Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 121: Georgia Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 122: North Carolina Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 123: Tennessee Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 124: South Carolina Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 125: Alabama Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 126: Mississippi Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 127: Louisiana Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 128: Arkansas Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 129: Kentucky Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 130: Oklahoma Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 131: Virginia Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 132: Maryland Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 133: West Virginia Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 134: Midwest Region U.S. Portable Point-of-Care Testing Devices Market: Regional Overview and Trends
TABLE 135: Midwest Region U.S. Portable Point-of-Care Testing Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 136: Midwest Region U.S. Portable Point-of-Care Testing Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 137: Midwest Region U.S. Portable Point-of-Care Testing Devices Market: Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
TABLE 138: Illinois Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 139: Ohio Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 140: Michigan Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 141: Minnesota Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 142: Indiana Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 143: Wisconsin Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 144: Missouri Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 145: Iowa Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 146: Kansas Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 147: Nebraska Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 148: North Dakota Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 149: South Dakota Portable Point-of-Care Testing Devices Market: Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 150: U.S. Portable Point-of-Care Testing Devices Market: Competitive Landscape Snapshot, 2025
TABLE 151: U.S. Portable Point-of-Care Testing Devices Market: Key Company Market Share Analysis, 2025
TABLE 152: U.S. Portable Point-of-Care Testing Devices Market: Company Positioning Matrix
TABLE 153: U.S. Portable Point-of-Care Testing Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 154: U.S. Portable Point-of-Care Testing Devices Market: CLIA-Waived Assay and Platform Benchmarking
TABLE 155: U.S. Portable Point-of-Care Testing Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 156: Abbott Laboratories / Abbott Point of Care: Company Profile
TABLE 157: Roche Diagnostics: Company Profile
TABLE 158: Siemens Healthineers: Company Profile
TABLE 159: Danaher Corporation / Cepheid: Company Profile
TABLE 160: QuidelOrtho Corporation: Company Profile
TABLE 161: bioMérieux / BIOFIRE Diagnostics: Company Profile
TABLE 162: Becton, Dickinson and Company: Company Profile
TABLE 163: Nova Biomedical: Company Profile
TABLE 164: Werfen: Company Profile
TABLE 165: EKF Diagnostics: Company Profile
TABLE 166: HemoCue: Company Profile
TABLE 167: Sekisui Diagnostics: Company Profile
TABLE 168: ACON Laboratories: Company Profile
TABLE 169: PTS Diagnostics: Company Profile
TABLE 170: ARKRAY: Company Profile
TABLE 171: QIAGEN: Company Profile
TABLE 172: Trinity Biotech: Company Profile
TABLE 173: SD Biosensor: Company Profile
TABLE 174: Sight Diagnostics: Company Profile
TABLE 175: PixCell Medical: Company Profile
TABLE 176: binx health: Company Profile
TABLE 177: Visby Medical: Company Profile
TABLE 178: Baebies: Company Profile
TABLE 179: OraSure Technologies: Company Profile
TABLE 180: Lumos Diagnostics: Company Profile
TABLE 181: U.S. Portable Point-of-Care Testing Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 182: U.S. Portable Point-of-Care Testing Devices Market: Disruptive Technologies Impact Matrix
TABLE 183: U.S. Portable Point-of-Care Testing Devices Market: Future CLIA-Waived Testing Landscape
TABLE 184: U.S. Portable Point-of-Care Testing Devices Market: Emerging Business Trends
TABLE 185: U.S. Portable Point-of-Care Testing Devices Market: Business Opportunities for Startups and Existing Players
TABLE 186: U.S. Portable Point-of-Care Testing Devices Market: Investment Prioritization Matrix
TABLE 187: U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations for Device Manufacturers
TABLE 188: U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations for Hospitals and Health Systems
TABLE 189: U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations for Physician Office and Urgent Care Networks
TABLE 190: U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 191: U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 192: U.S. Portable Point-of-Care Testing Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 193: U.S. Portable Point-of-Care Testing Devices Market: Go-to-Market Strategy Considerations
TABLE 194: U.S. Portable Point-of-Care Testing Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 195: U.S. Portable Point-of-Care Testing Devices Market: State-Level Commercial Prioritization Strategy
TABLE 196: U.S. Portable Point-of-Care Testing Devices Market: Scope Limitation
TABLE 197: U.S. Portable Point-of-Care Testing Devices Market: Data Use Limitation
TABLE 198: U.S. Portable Point-of-Care Testing Devices Market: Market Sizing Limitation
TABLE 199: U.S. Portable Point-of-Care Testing Devices Market: Forecasting Limitation
TABLE 200: U.S. Portable Point-of-Care Testing Devices Market: Regulatory and Reimbursement Information Limitation
TABLE 201: U.S. Portable Point-of-Care Testing Devices Market: Legal Disclaimer
TABLE 202: U.S. Portable Point-of-Care Testing Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Portable Point-of-Care Testing Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: U.S. Portable Point-of-Care Testing Devices Market: Market Attractiveness Analysis
FIGURE 5: U.S. Portable Point-of-Care Testing Devices Market: Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Portable Point-of-Care Testing Devices Market: Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Portable Point-of-Care Testing Devices Market: Year-wise Growth Curve, 2021–2035
FIGURE 8: U.S. Portable Point-of-Care Testing Devices Market: Market Dynamics
FIGURE 9: U.S. Portable Point-of-Care Testing Devices Market: Innovation & Patent Landscape, 2021–2025
FIGURE 10: U.S. Portable Point-of-Care Testing Devices Market: Clinical Workflow Economics Framework
FIGURE 11: U.S. Portable Point-of-Care Testing Devices Market: Hospital and Health System Procurement Decision Framework
FIGURE 12: U.S. Portable Point-of-Care Testing Devices Market: PESTEL Analysis
FIGURE 13: U.S. Portable Point-of-Care Testing Devices Market: Porter’s Five Forces Analysis
FIGURE 14: U.S. Portable Point-of-Care Testing Devices Market: Value Chain Analysis
FIGURE 15: U.S. Portable Point-of-Care Testing Devices Market: Supply Chain Analysis
FIGURE 16: U.S. Portable Point-of-Care Testing Devices Market: FDA–CLIA–Reimbursement Pathway Framework
FIGURE 17: U.S. Portable Point-of-Care Testing Devices Market: Connected Diagnostics and Point-of-Care Governance Framework
FIGURE 18: Product Type Segment Market Share Analysis, 2025 & 2035
FIGURE 19: Product Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 20: Handheld Blood Chemistry and Blood Gas Analyzers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 21: Portable Glucose, HbA1c and Metabolic Testing Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 22: Portable Immunoassay and Rapid-Test Readers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 23: Portable Molecular Diagnostic Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Portable Coagulation, Hematology and Urinalysis Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 26: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: Diabetes and Metabolic Disease Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: Infectious Disease Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Emergency and Critical Care Testing Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 30: Coagulation and Hematology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Renal, Urinalysis, Women’s Health and Other Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 33: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Hospitals and Emergency Departments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Physician Offices, Urgent Care and Retail Clinics Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: Ambulatory and Specialty Care Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 37: EMS, Rural, Community and Mobile Health Settings Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Home-Centered and Decentralized Care Providers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 40: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Electrochemical and Biosensor Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Immunoassay and Fluorescence Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Molecular NAAT and PCR Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 44: Microfluidic and Lab-on-Chip Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Optical, Photometric and Digital Imaging Technology Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Procurement Channel Segment Market Share Analysis, 2025 & 2035
FIGURE 47: Procurement Channel Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: Direct Hospital and Health System Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Integrated Delivery Network Enterprise Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Group Purchasing Organization Contracts Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 51: Distributor and Specialty Supplier Sales Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 52: Ambulatory, Office-Based and Decentralized Care Procurement Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 53: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 54: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 55: West Region U.S. Portable Point-of-Care Testing Devices Market: Market Share and Leading Players, 2025
FIGURE 56: West Region Market Share Analysis by State, 2025
FIGURE 57: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 58: California Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Washington Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Arizona Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 61: Colorado Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 62: Oregon Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: Utah Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 64: Nevada Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: New Mexico Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Idaho Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Montana Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Wyoming Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Alaska Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Hawaii Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: Northeast Region U.S. Portable Point-of-Care Testing Devices Market: Market Share and Leading Players, 2025
FIGURE 72: Northeast Region Market Share Analysis by State, 2025
FIGURE 73: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: New York Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Massachusetts Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: New Jersey Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Pennsylvania Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 78: Connecticut Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 79: Maine Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Vermont Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 81: New Hampshire Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Rhode Island Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: Delaware Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: South Region U.S. Portable Point-of-Care Testing Devices Market: Market Share and Leading Players, 2025
FIGURE 85: South Region Market Share Analysis by State, 2025
FIGURE 86: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Texas Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: Florida Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Georgia Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: North Carolina Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: Tennessee Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 92: South Carolina Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 93: Alabama Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: Mississippi Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 95: Louisiana Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Arkansas Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Kentucky Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: Oklahoma Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Virginia Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: Maryland Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: West Virginia Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Midwest Region U.S. Portable Point-of-Care Testing Devices Market: Market Share and Leading Players, 2025
FIGURE 103: Midwest Region Market Share Analysis by State, 2025
FIGURE 104: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Illinois Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Ohio Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Michigan Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Minnesota Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: Indiana Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Wisconsin Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 111: Missouri Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 112: Iowa Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Kansas Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 114: Nebraska Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: North Dakota Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: South Dakota Portable Point-of-Care Testing Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 118: Company Positioning Matrix
FIGURE 119: Key Player Product Portfolio Benchmarking
FIGURE 120: CLIA-Waived Assay and Platform Benchmarking
FIGURE 121: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 122: Portable Point-of-Care Testing Innovation Roadmap
FIGURE 123: Ultra-Fast Molecular Testing Adoption Roadmap
FIGURE 124: AI-Enabled Hematology Opportunity Map
FIGURE 125: Connected Point-of-Care Diagnostics Growth Roadmap
FIGURE 126: Future Market Scenario Analysis, 2026–2035
FIGURE 127: Disruptive Technologies Impact Matrix
FIGURE 128: Emerging Business Trends Matrix
FIGURE 129: Investment Prioritization Matrix
FIGURE 130: Strategic Growth Roadmap for U.S. Portable Point-of-Care Testing Device Companies
FIGURE 131: Go-to-Market Strategy Framework
FIGURE 132: Product Positioning and Portfolio Expansion Framework
FIGURE 133: State-Level Commercial Prioritization Framework
FIGURE 134: Report Scope and Disclaimer Framework